Replies to post #114042 on Amarantus Bioscience Holdings Inc (AMBS)

[zoomboom]

On track for Q2 15 according to AMBS CEO

[JPetroInc]

Eltoprazene P2B Trial Commencement 'On Track' for 2Q15



http://ir.amarantus.com/company-news/detail/1990/amarantus-receives-notice-of-allowance-for-u-s-patent-application-covering-proprietary-methods-of-administration-and-compositions-in-the-treatment-of-parkinsons-disease

SAN FRANCISCO and GENEVA, Switzerland, May 13, 2015 - "Eltoprazine, a small molecule 5HT1A/1B partial agonist, is currently preparing to commence Phase 2b clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). PD-LID is an abnormal involuntary, movement disorder resulting from prolonged levodopa-based therapy, the most commonly prescribed treatment for Parkinson's disease (PD). PD-LID occurs in approximately 60-80% of PD patients and is one of the most difficult problems facing people with the disease. This dyskinesia can be severely disabling and impact quality of life by prohibiting the ability to perform routine daily functions.

This Notice of Allowance for eltoprazine in Parkinson's is a meaningful addition to the intellectual property estate we have established related to eltoprazine and comes at an important time as we are gearing up to commence enrollment and patient dosing in our Phase 2b program in PD-LID," said Gerald E. Commissiong, President & CEO of Amarantus. "We believe eltoprazine has tremendous potential as an important therapy to address a significant unmet need and improve the quality of life for individuals with Parkinson's disease and their families. Amarantus expects to initiate patient enrollment and dosing in a 60-subject Phase 2b clinical study with eltoprazine in individuals with PD in the second quarter of 2015."